Research Article
Low-Dose Ketamine Infusion for Perioperative Pain Management in Patients Undergoing Laparoscopic Gastric Bypass: A Prospective Randomized Controlled Trial
Table 5
Data on the adverse events and side effects that occurred.
| Adverse events and side effects | | C | K | Total | value | (N = 18) | (N = 17) | (N = 35) | |
| Avg. RASS 1st 12 hours | | | | 0.19731 | Number | 18 | 17 | 35 | | Mean (SD) | −0.6 (0.3) | −0.5 (0.4) | −0.6 (0.4) | | Range | (−1.1–0.0) | (−1.8–0.3) | (−1.8–0.3) | |
| Avg. RASS 2nd 12 hours | | | | 0.78691 | Number | 18 | 17 | 35 | | Mean (SD) | 0.0 (0.1) | 0.0 (0.2) | 0.0 (0.1) | | Range | (−0.5–0.0) | (−0.7–0.0) | (−0.7–0.0) | |
| Avg. RASS 2nd 24 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Agitation 1st 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Agitation 2nd 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Agitation 2nd 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Adverse hemodynamic events | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Delirium 1st 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Delirium 2nd 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Delirium 2nd 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Diplopia 1st 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Diplopia 2nd 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Diplopia 2nd 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Hallucinations 1st 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Hallucinations 2nd 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Hallucinations 2nd 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Respiratory depression 1st 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Respiratory depression 2nd 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Respiratory depression 2nd 12 hours | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Nausea 1st 12 hours | | | | 0.84521 | N | 8 (44.4%) | 7 (41.2%) | 15 (42.9%) | | Y | 10 (55.6%) | 10 (58.8%) | 20 (57.1%) | |
| Nausea 2nd 12 hours | | | | 0.20761 | N | 15 (83.3%) | 11 (64.7%) | 26 (74.3%) | | Y | 3 (16.7%) | 6 (35.3%) | 9 (25.7%) | |
| Nausea 2nd 24 hours | | | | 0.93871 | N | 15 (83.3%) | 14 (82.4%) | 29 (82.9%) | | Y | 3 (16.7%) | 3 (17.6%) | 6 (17.1%) | |
| Length of stay (hours) | | | | 0.18242 | Number | 18 | 17 | 35 | | Mean (SD) | 36.6 (13.6) | 43.9 (18.0) | 40.1 (16.1) | | Range | (24–72.5) | (28.0–102.0) | (24.0–102.0) | |
| Pruritus | | | | 1.00001 | N | 18 (100%) | 17 (100%) | 35 (100%) | |
| Readmission | | | | 0.15701 | N | 16 (88.9%) | 17 (100.0%) | 33 (94.3%) | | Y | 2 (11.1%) | 0 (0.0%) | 2 (5.7%) | |
|
|
Lists data on the adverse events and side effects that occurred. Avg: average; Resp: respiratory; and RASS: Richmond agitation-sedation scale.
|